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Background: The association of systemic mastocytosis (SM) with a non-mast cell haematological neoplasm represents
a specific subtype of mastocytosis termed systemic mastocytosis with associated haematological non-mast cell disease
(SM-AHNMD). The overwhelming majority of the associated neoplasms are of myeloid origin, while lymphoid
neoplasms associated with SM have been reported rarely. Association of SM with Hodgkin’s lymphoma (HL) is
exceedingly rare; so far, only two cases of HL as associated hematological non-mast cell disease in systemic mastocytosis
have been published in the recent English literature.
Case: We present a case of a 37-year-old otherwise healthy male who was referred to our institution because of a
one-month lasting dysphagia of both hard and liquid food. Physical examination showed tumour in the left jugular
area measuring 2 cm in the largest diameter while computer tomography of the thorax revealed a 5.2 cm large,
hypodense, soft tissue tumour between the trachea and left arteria carotis communis. On the basis of FNAB findings,
the diagnosis of a “neutrophil-rich” Hodgkin’s lymphoma was established. Excisional biopsy of mediastinal tumor
showed lymphoid neoplasm with morphology and immunophenotype consistent with nodular sclerosis classical
Hodgkin’s lymphoma (NScHL). Bone marrow trephine biopsy and the MGG-stained smear of the bone marrow aspirate
performed for lymphoma staging revealed an existence of systemic mastocytosis which was unexpected and incidental
finding. Mast cells were highlighted by CD117 and tryptase immunostainings while CD25 positivity of mast cells was
consistent with their neoplastic phenotype.There were no HL infiltrates present in the bone marrow.
Conclusion: We report a very rare combination of systemic mastocytosis with Hodgkin’s lymphoma as associated
clonal haematological non-mast cell lineage disease. Systemic mastocytosis was an unexpected finding. The diagnosis
of SM in bone marrow in our case was straight-forward, but it can be difficult in the case of reactive lymphoid
aggregates or a difficult distinction between SM and HL infiltration. In particular, distinction can be challenging from
the immunohistochemical point of view in the case of high-grade mast cell disease which can be CD30 positive.
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Figure 1 Reed-Sternberg cells were rare and mainly found at
the edge of the smear (Giemsa, 60X).
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Mastocytosis is the result of a clonal, neoplastic prolifer-
ation of mast cells that accumulate in one or more organ
systems. It is characterized by the presence of multifocal
clusters or aggregates of abnormal mast cells. In the last
WHO classification [1] of tumours of haematopoietic
and lymphoid tissues, seven subtypes of mastocytosis are
defined by the distribution of the disease and its clinical
manifestations: cutaneous mastocytosis (CM), indolent
systemic mastocytosis (ISM), systemic mastocytosis with
associated clonal haematological non-mast cell lineage
disease (SM-AHNMD), aggressive systemic mastocytosis
(ASM), mast cell leukaemia (MCL), mast cell sarcoma
(MCS) and extracutaneous mastocytoma. In CM, mast
cell infiltrates are restricted to the skin, whereas systemic
mastocytosis (SM) is characterised by involvement of at
least one extracutaneous organ with or without involve-
ment of the skin. Bone marrow is almost always involved
in SM [1].
The association of systemic mastocytosis with a non-
mast cell haematological neoplasm represents a specific
subtype of mastocytosis termed SM-AHNMD [1]. It is
the second most frequent variant of SM [2]. The over-
whelming majority of the associated neoplasms are of
myeloid origin, while lymphoid neoplasms associated
with SM have been reported rarely [3-6]. Association of
SM with Hodgkin’s lymphoma has to be exceedingly
rare; a review of the recent English literature on coexist-
ence of Hodgkin’s lymphoma and systemic mastocytosis
resulted in only two published articles so far [7,8]. The
objective of this study is to report the clinical and patho-
logical features of a 37-year-old male patient who was
diagnosed with Hodgkin’s lymphoma of the upper medi-
astinum and indolent systemic mastocytosis which was
found incidentally from bone marrow trephine biopsy
performed for lymphoma staging.
Case presentation
A 37-year-old otherwise healthy male was referred to
our institution because of a one-month lasting dysphagia
of both hard and liquid food. He denied any breathing
difficulties. There was no evidence of systemic symp-
toms. Physical examination showed tumour in the left
jugular area measuring 2 cm in the largest diameter and
some small, unsuspicious lymph nodes on both sides of
the neck. The liver and spleen were not enlarged. There
were no skin lesions. Peripheral blood counts were
within normal limits. Serologies for anti-HAV, HbsAg,
anti- HBc, anti-Hbs, anti-HCV and HIV were all nega-
tive. Lately performed laboratory studies revealed that
the patient’s serum tryptase level was 79 ng/ml (normal
2–10). Fine-needle aspiration biopsy (FNAB) of jugulare
tumour was performed as part of the initial diagnostic
procedure, but the sample obtained was not diagnostic.Computer tomography of the thorax revealed a 5.2 cm
large, hypodense, soft tissue tumour between the trachea
and left arteria carotis communis, and subsequent
ultrasound-guided FNAB was performed. The tumour
was situated at the level of the upper thoracic opening.
Cytologically, the diagnosis of a “neutrophil-rich” Hodgkin’s
lymphoma was established. Excisional biopsy of the
tumour was performed to confirm the cytological findings.
Bone marrow involvement with lymphoma was assessed
by aspiration and trephine biopsy.
Cytological and pathological findings
The Giemsa-stained smear of the mediastinal tumour
was very cellular. Neutrophils predominated, obscuring
a few tumour cells found mainly along the edge of the
smear. Tumour cells which were not degenerated showed
moderately abundant, pale cytoplasm and single or mul-
tiple lobulated nuclei (Figure 1). Chromatin was finely
granular. Nucleoli were conspicuous only in some cells. In
a dense neutrophilic background, some histiocytes, few
eosinophils, fibrin fibres and proteinaceous granular ma-
terial were also observed. Because of the typical cytological
picture and despite the fact that additional immunophe-
notypic analyses could not be performed (due to lack of
tumour cells in the slides prepared for immunocytochem-
istry), the diagnosis of a “neutrophil-rich” Hodgkin’s
lymphoma was suggested.
Excisional biopsy of the mediastinal tumour revealed a
lymphoid neoplasm composed of relatively rare mono-
nuclear Hodgkin’s and binuclear Reed-Sternberg cells
residing in an infiltrate consisting of neutrophils, small
lymphocytes, plasma cells, eosinophils and histiocytes
(Figure 2). Some of the H-RS cells showed a retraction of
the cytoplasmic membrane, creating the appearance of the
so-called lacunar cells. Focally, HRS cells had more lobu-
lated nuclei with smaller lobes. On the periphery of the
Figure 2 H&E staining of mediastinal tumor, 10X; CD 30 and PAX 5 positive HRS cells, 20X.
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atypical cells were immunohistochemically positive for
CD30, CD15, Pax5 and MUM1 (Figure 2). In situ hybrid-
isation for EBV was negative. Based on the morphology
of the H-RS cells, reactive infiltrate and present fibrosis,
the tumour was classified as nodular sclerosis classical
Hodgkin’s lymphoma (NScHL).
Bone marrow trephine biopsy and the MGG-stained
smear of the bone marrow aspirate performed for
lymphoma staging revealed a slightly hypercellular bone
marrow with some smaller clusters of atypical mast cells
and a large peritrabecular infiltrate composed of atypical
mastocytes and lymphocytes (Figure 3). Mast cells were
highlighted by CD117 and tryptase immunostainings
(Figure 4). CD25 and CD2 positivity of mast cells was con-
sistent with their neoplastic phenotype (Figure 5). There
were no HL infiltrates present in the bone marrow.
Discussion
According to the current WHO classification, patients
with SM and concurrent haematological malignancy, ei-
ther myeloid or lymphoid, are included in the group of
so-called SM-AHNMD. Neoplasms associated with SMFigure 3 Trephine bone marrow biopsy – mastocyte infiltrate,
H&E 40X.are mainly of myeloid origin, while lymphoproliferative
diseases (LPD) are described only occasionally. It has
been shown that in the case of SM associated with mye-
loid malignancies, the neoplastic mastocytes and malig-
nant myeloid cells are clonally related, and both diseases
are often diagnosed concurrently [9,10]. In contrast, pa-
tients with SM and LPD usually have a long history of
indolent SM; LPD and SM clones are distinct [4]. The
present case of SM-cHL is interesting in several aspects.
First of all, the cytological picture of the mediastinal
tumour was unusual because it mimicked suppurative
lymphadenitis. Secondly, coexistence of HL and SM is
exceedingly rare. To the best of the authors’ knowledge,
only two cases have been described in the English litera-
ture so far. Last but not least, patients with SM and LPD
usually have a long history of indolent SM, which was
not present in our patient.
From the cytological aspect, only a few cases of Hodgkin’s
lymphoma with numerous neutrophils have been de-
scribed in the literature so far [11-14]. Histologically, these
cases have been mostly classified as nodular sclerosis cHL,
and only few of them as mixed cellularity cHL [11-14].
Such cases could be challenging because a predominanceFigure 4 Mastocytes highlighted by immunostaining for CD
117, 20X.
Figure 5 Abberant expression of CD25 on mastocyte cells, 60X.
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diagnostic Reed-Sternberg and Hodgkin cells, and they
can be misdiagnosed as suppurative lymphadenitis [11-14].
To avoid a false-negative cytological diagnosis, an accurate
search for Reed-Sternberg and Hodgkin cells must be
carry out. In the differential diagnosis of “neutrophil-rich”
HL and suppurative lymphadenitis, “neutrophil-rich” ana-
plastic large T-cell lymphoma (ALCL) and metastatic car-
cinoma must be considered. Suppurative lymphadenitis is
most commonly found in tuberculosis, Calmette Guerin
bacillus and atypical mycobacterial infection, Kikuchi’s
disease, cat-scratch disease, and lymphogranuloma vener-
eum [13,14]. Identification of the infectious agent is cru-
cial for the diagnosis, therefore a part of the FNAB sample
must be sent for microbiological testing. “Neutrophil-rich”
ALCL may be difficult to differentiate from “neutrophil-
rich” Hodgkin’s lymphoma. Immunocytochemical staining
for CD30, CD15, ALK, CD45, CD20, EMA and T-cell
markers can resolve this differential diagnostic dilemma
[15,16]. Metastatic carcinoma could also represent a dif-
ferential diagnostic possibility. Metastatic squamous-cell
carcinoma is particularly prone to necrosis and inflamma-
tion, which in many cases leads to the cytological picture
that can be very similar to that in “neutrophil-rich” HL or
ALCL [14]. However, this dilemma could be easily solved
by cytokeratin immunocytochemical staining.
Coexistence of SM with HL might be challenging also
in terms of separation of bone marrow infiltrates. React-
ive lymphoid aggregates are a feature of bone marrow
infiltrates in patients with indolent SM. They can be
composed of a mixture of mast cells and lymphocytes, or
either of them may predominate [17]. As well, increased
eosinophils can accompany lymphocytes as a part of the
background infiltrate not only in systemic mastocytosis
but also in HL. Since HL is also characterised by a paucity
of neoplastic cells in comparison to background reactive
cells, morphological similarity between the infiltrates ofSM and HL could cause confusion; either of them can be
misdiagnosed. Furthermore, aggressive mastocytosis (ASM)
is morphologically characterised by a marked degree of
bone marrow infiltration that can be diffuse or focal. Its
major differential diagnosis is SM-AHNMD since AHNMD
may be almost obscured by the massive mast cell infiltrate
[18]. Besides, it has been shown that a major proportion
of cases with high-grade SM (ASM, SM-AHNMD and
mast cell leukaemia) show a strong expression of CD30 by
a majority of neoplastic mast cells [18]. All of the above-
mentioned, as well as CD30 positivity of mast cells, may
result in the misinterpretation of bone marrow infiltration
by HL, unless antitryptase staining is performed, and may
contribute to erroneous tumour staging and treatment.
Conclusions
In conclusion, we report a very rare combination of sys-
temic mastocytosis with Hodgkin’s lymphoma as associ-
ated clonal haematological non-mast cell lineage disease.
In our case, HL was presented as a mediastinal tumour
and sub-classified as nodular sclerosis. Systemic masto-
cytosis was an unexpected finding. To our knowledge,
this is the third reported case in the literature of such
disease combination.
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